ArticleInfection2026
From bench to triage: diagnostic utility of delta-like canonical notch ligand-1 (DLL-1) for early sepsis prediction in the emergency department.
Article in Infection, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe early identification of patients with sepsis among those presenting with suspected infection in the emergency department (ED) remains challenging. Delta-like canonical Notch ligand-1 (DLL-1), a Notch pathway ligand involved in immune and endothelial signaling, has been shown to reflect disease severity and outcomes in ICU-based sepsis cohorts. Its value for early risk stratification at ED presentation is less well defined.
methodsWe analyzed DLL-1 concentrations in serum samples from a prospectively enrolled ED cohort of adults presenting with clinically suspected acute infection. Blood samples were obtained during the initial clinical assessment. Sepsis was defined according to Sepsis-3 criteria and adjudicated by an expert panel, including evaluation of organ dysfunction within 72 h after presentation. DLL-1 concentrations were measured using enzyme-linked immunosorbent assay (ELISA), and diagnostic performance was assessed using AUROC analysis.
resultsAmong 300 enrolled patients, 74 (24.7%) were classified as having sepsis. DLL-1 concentrations were significantly higher in patients with sepsis than in those without sepsis (median 11,454 vs. 8,085 pg/mL; p < 0.001). DLL-1 demonstrated moderate discriminatory performance for sepsis at ED presentation (AUROC 0.69, 95% CI 0.62-0.76). Performance was lower than that of procalcitonin and NEWS2 but comparable to C-reactive protein and lactate. DLL-1 showed a moderate correlation with SOFA score. Importantly, correlations with CRP and white blood cell count were nonsignificant.
conclusionsWhen measured at ED presentation, DLL-1 concentrations are elevated in patients with sepsis but showed only moderate diagnostic performance. These findings are consistent with earlier disease stages and lower degrees of organ dysfunction compared with ICU populations. DLL-1 may offer complementary host-response information beyond established biomarkers, but does not support stand-alone use for early sepsis diagnosis and warrants further evaluation within multimodal risk stratification strategies.
trial registrationDRKS00017395.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.